Literature DB >> 5155758

Hemodynamic interference of alprenolol with dihydralazine in normal and hypertensive man.

R Sannerstedt, J Stenberg, G Johnsson, L Werkö.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5155758     DOI: 10.1016/0002-9149(71)90120-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  7 in total

Review 1.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

2.  Comparative study of alprenolol and methyldopa in previously untreated essential hypertension.

Authors:  J A Vedin; C E Wilhelmsson; L Werkö
Journal:  Br Heart J       Date:  1973-12

3.  Cardiovascular effects of alinidine and propranolol alone and in combination with hydralazine in normal man.

Authors:  D P Nicholls; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

4.  Antihypertensive therapy with adrenergic beta-receptor blockers and vasodilators.

Authors:  W Aenishänslin; J Pestalozzi-Kerpel; U C Dubach; P R Imhof; M Turri
Journal:  Eur J Clin Pharmacol       Date:  1972-06       Impact factor: 2.953

5.  Treatment of hypertension successively with a diuretic, clonidine or a beta-blocking agent and hydralazine.

Authors:  T Pitkäjärvi; P Ala-Laurila; R Ruosteenoja; P Torsti; S E Masar
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

6.  Mechanism of the interaction of propranolol and a potent vasodilator antihypertensive agent - minoxidil.

Authors:  K O'Malley; M Velasco; J Wells; J McNay
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

7.  Hypotensive effect of oxprenolol in mild to moderate hypertension: a multicentre controlled study.

Authors:  M Motolese; G Muiesan; A Colombi
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.